Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Efficacy and Safety of Mexiletine in Non-dystrophic Myotonias

Next Previous
Trial Profile

Efficacy and Safety of Mexiletine in Non-dystrophic Myotonias

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 20 Jan 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Mexiletine (Primary)
  • Indications Myotonia; Myotonic disorders
  • Focus Registrational; Therapeutic Use
  • Acronyms MYOMEX

    • Most Recent Events

    • 07 Jan 2019 According to a Lupin media release, based on the data from this and other studies (randomized, placebo-controlled clinical study and an observational study), the European Commission has approved NaMuscla(mexiletine hydrochloride) for the symptomatic treatment of myotonia in adults with non-dystrophic myotonic disorders. The approval will apply to all 28 countries of the European Union, Norway, Iceland and Liechtenstein.
    • 30 Oct 2018 New trial record
    • 19 Oct 2018 According to a Lupin media release, based on the data from this and other three controlled clinical studies the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMA), has adopted a positive opinion recommending the marketing authorization of NaMuscla (mexiletine hydrochloride) for the symptomatic treatment of myotonia in adults with non-dystrophic myotonic (NDM) disorders.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top